AntibioTx Announces Positive Data Supporting the Safety of ATx201
COPENHAGEN, JUNE 25, 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders, has with the addition of two preclinical studies (Ocular Irritation and Phototoxicity) further strengthened ATx201’s safety […]
AntibioTx Strengthens Management Team with CFO and VP of Commercialization
COPENHAGEN, APRIL 02, 2018 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the company has expanded the management team with Morten Boesen as […]
FDA Approves IND to Conduct Clinical Studies with ATx201 in USA
COPENHAGEN, NOVEMBER 01 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that the U.S Food and Drug Administration (FDA) has granted an Investigational […]
AntibioTx Signs 150 M DKK Financing Agreement with the European Investment Bank
COPENHAGEN, OCTOBER 26, 2017 – AntibioTx A/S has signed a 150 M DKK (20 M EUR) financing agreement with the European Investment Bank to support late-stage clinical trials for the […]
AntibioTx to Present Phase I DECOLAD Results at the 26th EADV
COPENHAGEN, JUNE 02, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders has been invited to present Phase I DECOLAD results at the Annual Congress of […]
AntibioTx Announces New Board Members
COPENHAGEN, MAY 22, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced three new board members. Joining AntibioTx board of directors are Stig Loekke […]
AntibioTx Announces Phase I Study Results for ATx201
COPENHAGEN, APRIL 05, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting inflammatory and microbiome-related disorders, today declared successful completion of a Phase I study with ATx201. The Study set out […]
AntibioTx Announces Reward of Grant Funding to Conduct Clinical Biomarker Study with ATx201
COPENHAGEN, MARCH 24 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting antimicrobial infections and microbiome-related disorders today announced that Antibiotx has been rewarded a grant from Innovation Fund Denmark to […]
AntibioTx Signs Dr. Philippe Prokocimer as Chief Medical Officer and Establishes US Subsidiary
AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders, has announced the appointment of Dr. Phillipe Prokocimer as new Chief Medical Officer. Dr. Prokocimer brings more than 30 years of […]
AntibioTx Expands Management Team with new VP of Drug Regulatory Affairs
COPENHAGEN, FEBRUARY 15, 2017 – AntibioTx, a clinical stage, pharmaceutical company targeting microbiome-related disorders today announced that Lutz Wevelsiep, Ph.D. will be appointed as AntibioTx new VP of Drug Regulatory Affairs. […]
